Russian Federation: Patent Extension In Russia

Since 2003 it has been possible to extend the duration or term of a Russian patent for a drug, pesticide or agricultural chemical by up to five years. Upon the patent holder's request, an extension to a patent term may be obtained based on the product's first marketing authorisation.

It used to be possible to extend patent claims related to a substance, antibody or pharmaceutical formulation, which included all possible alternatives covered in the corresponding patent claim. However, in 2015 the regulations were tightened and it is now possible to extend patent claims that covered a commercial product whose use was permitted by a marketing authorisation only.

According to the new legislation, an additional patent with restricted claims is issued instead of an extension. The additional patent's claims do not contain alternative features – they are directly related to the product whose use was permitted by the authorisation. Claims directed to use, process, expression vectors and cells, among others (ie, that do not cover the commercial product) are not subject to extensions.

An additional patent for a drug, pesticide or agricultural chemical may be issued if more than five years have passed from the application filing date to the date when the marketing authorisation was obtained. The term of the additional patent cannot exceed five years and is calculated by using the date when the marketing authorisation was obtained, minus the submission date and then minus five years. In order to obtain an additional patent, the patent holder must submit a request to the Russia Patent and Trademark Office (Rospatent) along with a notarised copy of the marketing authorisation and the amended claims that constitute the claims limited to a specific product. For example, if a patent has a Markush claim, then the values of all substitutes will be limited by a single value in the additional patent, in such a way that the Markush claim covers one compound only.

A patent-term extension request is usually reviewed by the same branch department that examined the initial patent application and by the same examiner. If the examiner decides that the amended claims do not comply with the legislative requirements, they can issue an office action. Generally, this happens if amended claims are insufficiently limited and have covered alternatives (eg, more than one compound in the case of a Markush claim). The time for responding to the office action, as well as the extension of time for responding, are the same as those for an application for an invention (ie, three months from the date of the office action issuance).

Rospatent has a fairly strict policy on patent-term extensions and tries to minimise the scope of legal protection provided by an additional patent. For example, when extending the patent term for a pharmaceutical composition, the examiner will try to narrow down the additional patent claims in such a way that the active ingredient content is limited not by a value range, but instead by one or several isolated values that correspond with the values specified in the marketing authorisation. Further, the examiner will try to limit the claims by specifying the excipients in the marketing authorisation and isolating the values of their composition. However, practice has shown that examiners are willing to meet patent holders halfway and ultimately keep an active ingredient composition range in additional patent claims, albeit narrowed down in comparison with the patent.

If the patent claims to a compound have the "pharmaceutically acceptable salt" feature, and the drug authorised for the market contains an active ingredient in the form of a salt only, the examiner will most likely keep the substance and the pharmaceutically acceptable salt feature in the additional patent claims. However, features such as solvates or hydrates will be excluded from additional patent claims if the drug's active ingredient is not one of these.

Therefore, in order to achieve the maximum scope of protection provided by an additional patent, the patent holder is required to provide convincing arguments that each feature kept in the changed claims is related to the drug authorised for the market. In other words, compulsory documents sent to Rospatent should be supplemented with an accompanying letter, which describes in detail how certain features of the claims are related to the commercial product. In this case, the arguments provided in the accompanying letter should be documented.

For example, proving the structure of a substance or antibody requires a copy from a World Health Organisation bulletin, in which the structure of the substance or antibody is given as well as its international non-proprietary name. If the patent claims include isomers, the patent holder should provide copies of the technical documents with regard to the production or qualitative analysis of the drug composition, which show that the composition has, at the very least, trace amounts of such isomers.

If the patent claims do not specify a defined crystalline form, one should provide relevant parts of the dossier with a description of the properties of this form. That said, there may be situations when patent claims use units (eg, cm-1) different from those in the dossier (eg, 2θ). In this case, the units from the dossier must be converted into the units from the claims in such a way that the values of these units coincide and the conversion algorithm must be shown in an accompanying letter.

If an original patent covers several compounds that are present in commercial products and each product has a separate marketing authorisation, it may be possible to obtain an additional patent for each of the compounds.

If one of the patent claims has both a compound and its active metabolite as alternatives, or if the active ingredient is an active metabolite and the patent claims protect a pro-drug, then the claims of an additional patent retain both compounds.

If the patent holder has two patents for different salts of the same substance, an additional patent will be granted to the salt contained in the drug only. The same approach will be adopted for different crystalline forms – an additional patent will be granted for the crystalline form that is present in the drug only.

After agreeing on the scope of claims, the patent holder will receive an additional patent with new claims, the corresponding record will be entered in the state registry and the additional patent claims will be published. Further, the patent will keep its previous number. The term of the additional patent is calculated from the day after the original patent expiry date.

The decision to reject a patent extension as well as the decision to extend a patent term can be challenged before the IP Court within three months.

Originally Published by IAM

"Read the original article on GowlingWLG.com"

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
19 Sep 2019, Seminar, Birmingham, UK

Providing GCs, Heads of Legal and senior in-house lawyers with timely, topical and practical legal advice on a variety of topics.

26 Sep 2019, Seminar, London, UK

Providing GCs, Heads of Legal and senior in-house lawyers with timely, topical and practical legal advice on a variety of topics.

8 Oct 2019, Seminar, Birmingham, UK

Supporting the development of paralegals, trainees and lawyers of up to five years' PQE by providing valuable knowledge and guidance together with practical tips.

Similar Articles
Relevancy Powered by MondaqAI
Gorodissky & Partners
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Gorodissky & Partners
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions